Pharma major Ind-Swift Laboratories Ltd, which has a strong basket of over 40 products across 16 therapeutic segments, has got the USFDA nod for two more DMFs Temozolomide and Telmisartan. Besides commercially supplying four molecules to the US, the company has hitherto filed 20 DMFs with the USFDA, of which all have been approved.
CNBC-TV18 special series for small and medium enterprises 'SME CEO Knowledge Series' discusses the strengths of the SME sector and the opportunities available to them to get them to a global stage.
Drugmakers want tax exemption deadline for export oriented unit (EOUs) to be extended and want infrastructure or priority sector status in the budget on Feb 28.
The transportation costs of Indian drug firms is expected to fall by 15% to 20% percent once a dispute between India and Europe over drug shipments is resolved, NR Munjal, president, Indian Drug Manufacturers' Association, told Reuters.